

Long non-coding RNA CASC15 promotes nasopharyngeal carcinoma cell proliferation and metastasis by downregulating miR-101-3p

M.-Y. XUE¹, H.-X. CAO²

¹Department of Otorhinolaryngology-Head and Neck Surgery, Affiliated Hospital of Jiangnan University (The Fourth People's Hospital of Wuxi), Wuxi, China

²Department of General Surgery, Affiliated Hospital of Jiangnan University (The Fourth People's Hospital of Wuxi), Wuxi, China

Abstract. – **OBJECTIVE:** Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors worldwide. Recent studies have revealed that long non-coding RNAs (lncRNAs) play important roles in the progression of tumorigenesis. The aim of this study was to identify the exact role of lncRNA CASC15 in the progression of NPC.

PATIENTS AND METHODS: CASC15 expression in both 54 paired NPC patients' tissue samples and cell lines was detected by Time-quantitative Polymerase Chain Reaction (RT-qPCR). Moreover, the function of CASC15 was identified by performing cell proliferation assay, transwell assay and wound healing assay *in vitro*. The underlying mechanism was explored through Luciferase assay and qPCR. In addition, tumor formation and metastasis assays were conducted *in vivo*.

RESULTS: CASC15 expression in tissues was markedly higher than that of adjacent non-tumor tissues. The proliferation, migration and invasion of NPC cells were significantly inhibited after knockdown of CASC15 *in vitro*. Our further experiments revealed that miR-101-3p was remarkably up-regulated. Knockdown of CASC15, meanwhile, miR-101-3p was a direct target of CASC15 in NPC. Furthermore, tumor formation and metastasis of NPC were significantly inhibited via knockdown of CASC15 in nude mice.

CONCLUSION: CASC15 enhances NPC cell proliferation and metastasis via sponging miR-101-3p *in vitro* and *in vivo*.

Key Words: miR-101-3p, CASC15, Nasopharyngeal carcinoma (NPC), miR-101-3p.

Introduction

Nasopharyngeal carcinoma (NPC) is one of the most common head and neck epithelial cancers worldwide, especially in Southern China and

Southeast Asia. NPC is characterized by poor or undifferentiated cancer. Due to the advances in modulated radiotherapy and combined chemotherapy, the prognosis of patients with local and regional NPC has been significantly improved. However, most NPC patients are already in advanced stages when initially diagnosed, with a median survival of 12 months^{2,3}. Therefore, it is urgent to formulate a better understanding of the molecular mechanisms of NPC progression.

Next-generation sequencing technology indicates that most genome sequence transcripts are non-coding RNAs (ncRNAs). Long non-coding RNA (lncRNA) is a subtype of ncRNA with longer than 200 nucleotides in length. Recently, research has revealed that lncRNAs function as key regulators in numerous biological processes, including the development of diverse cancers. For example, knockdown of lncRNA MNX1-AS1 inhibits the proliferation and migration of ovarian cancer cells. Meanwhile, it may be a potential therapeutic target for ovarian cancer⁴. By depressing tumor suppressor miR-143, lncRNA UCA1 functions as an oncogene in breast cancer and participates in the modulation of cell growth and apoptosis⁵. lncRNA RUNX1-IT1 acts as a tumor suppressor in colorectal cancer by inhibiting cell migration and cell proliferation⁶. Furthermore, overexpression of lncRNA NNT-AS1 facilitates the proliferation and invasion of cervical cancer cells through the Wnt/beta-catenin signaling pathway⁷.

Our study demonstrated that CASC15 was remarkably up-regulated in NPC tissues and cell lines. Moreover, knockdown of CASC15 significantly inhibited the proliferation and invasion of NPC *in vitro* and *in vivo*. In addition, our findings indicated that the function of CASC15 in NPC was associated with miR-101-3p.

Patients and Methods

Tissue Specimens

54 paired tumor tissues and adjacent non-tumor tissues were sequentially gathered from NPC patients who underwent surgery in the Affiliated Hospital of Jiangnan University. All patients were diagnosed with NPC by two independent pathologists without any controversial. This study was approved by the Ethics Committee of the Affiliated Hospital of Jiangnan University. Informed consents were obtained from all participants before the study.

Cell Culture

NPC cancer cell lines (CNE2, CNE1, 5-8F and 6-18B) and immortalized normal nasopharyngeal epithelial cell line (NP69) were purchased from the Chinese Academy of Science (Shanghai, China). All cells were maintained in Roswell Park Memorial Institute-1640 (RPMI-1640; HyClone, South Logan, UT, USA) containing 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) and penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA). Besides, the cells were cultured in an incubator containing 5% CO₂ at 37°C.

Cell Transfection

Lentivirus expressing short-hairpin RNA (shRNA) directly against CASC15 was provided by GenePharma (Shanghai, China). Negative control shRNA was synthesized as well. Briefly, CASC15 shRNA or negative control shRNA was transfected into NPC cells according to the manufacturer's protocol of Lipofectamine 3000 reagent (Invitrogen, Carlsbad, CA, USA).

RNA Extraction and Real Time-Quantitative Polymerase Chain Reaction (RT-qPCR)

Total RNA was extracted from NPC cells or tissue samples using Trizol reagent (TaKaRa, Giga, Japan). Extracted RNA was then reverse transcribed into complementary deoxyribonucleic acids (cDNAs) through the reverse transcription kit (TaKaRa, Otsu, Shiga, Japan). Primer sequences used for Real Time-Quantitative Polymerase Chain Reaction (RT-qPCR) were as follows: CASC15 forward: 5'-CACACGCATGGAAAACCCAG-3' and reverse: 5'-GAGGACCTGAGCTGTAAGCC-3'; Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), forward: 5'-GCACCGTCAAGGCT-

GAGAAC-3' and reverse: 5'-TGGTGAAGAC-GCCAGTGGA-3'. The specific procedure for PCR was as follows: pre-denaturation at 95°C for 1 min, followed by 40 cycles at 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. Relative expression was calculated by the $2^{-\Delta\Delta Ct}$ method. This experiment was repeated three times.

Cell Proliferation Assay

Cell viability was monitored according to the instructions of Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Kumamoto, Japan) assay. Briefly, NPC CNE1 cells were seeded into 96-well plates. Eight hours after incubation with CASC15 shRNA or control, the cells were incubated with 10 μ L of CCK-8 for 3 h in the dark. Absorbance at 450 nm was measured by an enzyme-linked immunosorbent assay (ELISA) reader system (Multiskan Ascent, LabSystems, Helsinki, Finland).

Scratch Wound Assay

Cells were first transferred into 6-well plates and cultured in RPMI-1640 medium overnight. After washed with a plastic tip, the cells were cultured in serum-free RPMI-1640. Wound closure was viewed at 48 h. Each assay was independently repeated three times.

Transwell Assay

Transwell chambers with 8 μ m pores were provided by Corning (Lowell, MA, USA). First, the membrane was pre-coated with 50 μ L Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). Subsequently, the cells were seeded into the upper chamber of a 24-well plate. Meanwhile, 20% FBS-RPMI-1640 was added to the lower chamber of culture inserts. After incubation for 24 h, these inserts were fixed with methanol for 30 min and stained with hematoxylin for 20 min. The number of migrated cells was counted under a light microscope (Olympus, Tokyo, Japan).

Luciferase Reporter Gene Assay

DIANA LncBASE Predicted v.2 was used to predict the potential target gene and fragment sequences containing CASC15 reaction sites. The Luciferase reporter gene assay (Promega, Madison, WI, USA) was used to detect the Luciferase activity of NPC cells. The Luciferase reporter gene vector was constructed and transfected into

CNE1 cells. CASC15 3'-untranslated region (3'-UTR) wild-type (WT) sequence named CASC15-WT was 5'-GGUGAGGAUCUUAUACUGUA-3', and mutant sequence of CASC15 3'-UTR missing the binding site with miR-101-3p named CASC15-MUT was 5'-GGUGAGGAUCUUAU-AUGACAU-3'.

Xenograft Model

For tumor formation assay, transfected CNE1 cells were subcutaneously injected into NOD/SCID mice (6 weeks old). Tumor diameters were detected every 5 days after inoculation. Tumor volume was calculated as the formula: volume = length \times width² \times 1/2. The mice were sacrificed, and tumors were extracted after 4 weeks. For tumor metastasis assay, transfected CNE1 cells were injected into the tail vein of NOD/SCID mice (6 weeks old). The mice were sacrificed, and lung tissues were extracted after 4 weeks. The number of metastatic nodules in lung tissues was counted. Animal experiments were approved by the Animal Ethics Committee of the Jiangnan University.

Statistical Analysis

Statistical Product and Service Solutions (SPSS) 21.0 (IBM Corp., Armonk, NY, USA) was used for all statistical analysis. Independent-sample *t*-test was used to compare the difference between the two groups. $p < 0.05$ was considered statistically significant.

Results

Expression Level of CASC15 in NPC Tissues and Cell Lines

RT-qPCR was first conducted to detect CASC15 expression in 54 patients' tissues and NPC cell lines. The results demonstrated that CASC15 was significantly up-regulated in tumor tissues than that of the adjacent normal tissues (Figure 1A). Compared with NP69 cells, CASC15 expression was markedly higher in NPC cell lines (Figure 1B).

Knockdown of CASC15 Repressed Proliferation and Metastasis of CNE1 NPC Cells

In our study, CNE1 cell line was chosen for knockdown of CASC15 *in vitro*. RT-qPCR was utilized to detect CASC15 expression (Figure 2A). CCK-8 assay showed that the growth ability of CNE1 cells was significantly repressed after CASC15 knockdown (Figure 2B). Scratch wound assay showed that the migrated length of CNE1 cells decreased markedly after CASC15 was knocked down (Figure 2C). Furthermore, transwell assay showed that the number of invaded cells was significantly reduced after knock-down of CASC15 (Figure 2D).

The Interaction Between MiR-101-3p and CASC15 in NPC

DIANA LncBASE Predicted v.2 was used to search for microRNAs that contained complementary base with CASC15. MiR-101-3p




Figure 1. Expression level of CASC15 increased significantly in NPC tissues and cell lines. **A**, CASC15 expression increased markedly in NPC tissues when compared with adjacent normal tissues. **B**, Expression levels of CASC15 relative to GAPDH in human NPC cell lines and immortalized normal nasopharyngeal epithelial cell line (NP69) were determined by RT-qPCR. Data were presented as mean \pm standard error of the mean. $*p < 0.05$.




Figure 2. Knockdown of CASC15 inhibited CNE1 NPC cell proliferation, migration and invasion. **A**, CASC15 expression in NPC cells transfected with negative control shRNA (NC) or CASC15 shRNA (sh-CASC15) was detected by RT-qPCR. GAPDH was used as an internal control. **B**, CCK-8 assay showed that knockdown of CASC15 significantly repressed the proliferation of NPC cells. **C**, Wound healing assay showed that the migrated length of NPC cells in sh-CASC15 group decreased markedly in comparison with the NC group (magnification: 40 \times). **D**, Transwell assay showed that knockdown of CASC15 significantly repressed the invasion of NPC cells (magnification: 40 \times). The results represented the average of three independent experiments. Error bars represent standard error of the mean. * $p < 0.05$, compared with control cells.

was identified as these miRNAs that were interacted with CASC15 (Figure 3A). RT-qPCR assay showed that the expression of miR-101-3p was significantly higher in sh-CASC15 cells than that of negative control shRNA cells (Figure 3B). The Luciferase reporter gene assay revealed that co-transfection of CASC15-WT and miR-101-3p remarkably decreased Luciferase

activity. However, no significant differences were observed in the Luciferase activity after co-transfection of CASC15-MUT and miR-101-3p (Figure 3C). In addition, the results of the linear correlation analysis showed that the expression of miR-101-3p was negatively correlated with CASC15 expression in NPC tissues (Figure 3D).




Figure 3. The association between CASC15 and miR-101-3p in NPC tissues. **A**, The binding sites of miR-101-3p on CASC15. **B**, The expression of miR-101-3p increased remarkably in the sh-CASC15 group when compared with negative control shRNA (NC) group. **C**, Co-transfection of miR-101-3p and CASC15-WT strongly decreased Luciferase activity, while co-transfection of miR-101-3p and CASC15-MUT did not affect Luciferase activity. **D**, Linear correlation between the expression level of miR-101-3p and CASC15 in NPC tissues. The results represent the average of three independent experiments. Data were presented as mean \pm standard error of the mean. * $p < 0.05$.

CASC15 Knockdown Inhibited Tumor Formation and Metastasis In Vivo

The ability of CASC15 in tumor formation and metastasis was detected *in vivo*. The results indicated that tumor size in the sh-CASC15 group was significantly smaller when compared with negative control shRNA group (Figure 4A). The weight of dissected tumor in sh-CASC15 group was remarkably smaller than that of negative control shRNA group (Figure 4B). Meanwhile, the number of metastatic nodules in lung tissues of the sh-CASC15 group was significantly reduced when compared with the negative control shRNA group (Figure 4C). Subsequently, the expression levels of CASC15 and miR-101-3p in dissected tumor tissues were detected by RT-qPCR. The results showed that CASC15 was lowly expressed in the sh-CASC15 group compared with the negative control shRNA group (Figure 4D). Howev-

er, miR-101-3p was highly expressed in the sh-CASC15 group when compared with the negative control shRNA group (Figure 4E).

Discussion

Currently, it has been reported that altered expressions of genes are associated with the progression of NPC. For example, lncRNA H19 promotes the invasion of NPC cells by regulating the expression of EZH2⁸. LncRNA-LET acts as a tumor suppressor gene in NPC by inhibiting the proliferation, adhesion and invasion of NPC cells⁹. By modulating miR-363-5p/S100A1 signaling pathway, lncRNA FOXD2-AS1 aggravates carcinogenesis of NPC¹⁰. Furthermore, the silence of lncRNA XIST suppresses the progression of NPC by acting as a sponge for miR-491-5p¹¹.




Figure 4. Knockdown of CASC15 inhibits tumor formation and metastasis of NPC *in vivo*. **A**, Tumor size in sh-CASC15 group was significantly smaller than that of the NC group. **B**, The weight of dissected tumors in the sh-CASC15 group was markedly smaller than that of the NC group. **C**, The number of metastatic nodules in lung tissues of the sh-CASC15 group was significantly reduced compared with the NC group. **D**, CASC15 was lowly-expressed in dissected tumors of sh-CASC15 group when compared with the NC group. **E**, MiR-101-3p was highly-expressed in dissected tumors of sh-CASC15 group compared with the NC group. The results represented the average of three independent experiments (mean \pm standard error of the mean). * $p < 0.05$ compared with control cells.

is a novel tumor susceptibility candidate 15 (CASC15, also known as LINC00340), was initially identified as an active lncRNA *in silico*. Lessard et al. have proved that overexpression of CASC15 promotes cell migration and phenotype switching in melanoma. CASC15 enhances the metastasis of hepatocellular carcinoma cells, which is also correlated with poor prog-

nosis of patients¹³. Up-regulation of CASC15 promotes cell proliferation in gastric cancer and functions as a risk factor for gastric cancer prognosis¹⁴. Moreover, CASC15 participates in RUNX1-rearranged acute leukemia by regulating the expression of SOX4¹⁵. In the present study, CASC15 was found significantly up-regulated in both NPC tissues and cell lines. Fur-

thermore, after CASC15 was knocked down, the growth, migration and invasion abilities of NPC cells were markedly suppressed. These results indicated that CASC15 functioned as an oncogene and promoted the tumorigenesis of NPC.

Recently, emerging studies have explored the relationship between the two subgroups of ncRNAs, namely lncRNAs and miRNAs. Researchers have found that lncRNAs function as molecular sponges or ceRNAs in regulating the expression of miRNAs, thereby achieving their biological functions in diverse cancers. In our work, bioinformatics software predicted that miR-101-3p was a possible target gene of CASC15 in NPC. Liu et al¹⁶ have evaluated the expression of miR-101-3p in tumors and its targeted genes. For instance, lncRNA SPRY4-IT1 promotes the progression of bladder cancer *via* upregulating EZH2. By inhibiting miR-101-3p, upregulation of lncRNA SNHG1 promotes the progression of non-small cell lung cancer *via* activating the Wnt/ β -catenin signaling pathway¹⁷. Through silencing p27 and sponging miR-101-3p, lncRNA SNHG6 facilitates cell invasion and proliferation in gastric cancer by regulating epithelial-mesenchymal transition¹⁸. Moreover, lncRNA SPRY4-IT1 enhances the proliferation and invasion of colorectal cancer cells by sponging as a ceRNA of miR-101-3p¹⁹. In this study, luciferases reporter gene assay indicated that miR-101-3p was directly targeted by CASC15 in NPC. Meanwhile, miR-101-3p expression was significantly up-regulated after knockdown of CASC15. Knockdown of CASC15 markedly inhibited tumor formation and metastasis *in vivo*. Meanwhile, the expression level of CASC15 was regulated by miR-101-3p in cultured tumor tissues after knockdown of CASC15 in nude mice. All these results showed that CASC15 acted as a miR-101-3p sponge in NPC.

Conclusions

CASC15 enhanced NPC cell proliferation and metastasis *in vivo* by sponging miR-101-3p. Our findings implied that lncRNA CASC15 could serve as a promising marker for NPC.

Conflict of Interest

The Authors declare that they have no conflict of interests.

References

- 1) KAMRAN SC, RIAZ N, LEE N. Nasopharyngeal carcinoma. *Surg Oncol Clin N Am* 2015; 24: 547-561.
- 2) NGEOW J, LIM WT, LEONG SS, ANG MK, TOH CK, GAO F, CHOWBAY B, TAN EH. Docetaxel is effective in heavily pretreated patients with distant metastases and nasopharyngeal carcinoma. *J Clin Oncol* 2011; 29: 718-722.
- 3) WEI F, WU Y, TANG L, HE Y, LIU X, XIONG F, CHENG Z, GUO C, LI X, LIAO Q, CHANG W, LIU M, YANG B, LI X, LI Y, LI G, XIONG Y, ZENG Z. BRIN3 (LINC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM. *Br J Cancer* 2018; 118: 274-287.
- 4) LV Y, LI H, LIU F, LIU H, LI X. Long noncoding RNA MNX1-IT1 knockdown inhibits cell proliferation and invasion in ovarian cancer. *Cancer Biother Radiopharm* 2017; 32: 91-99.
- 5) TUO YL, LI XM, LIU J. Long noncoding RNA UCA1 regulates breast cancer cell growth and apoptosis through decreasing tumor suppressive miR-143. *Eur Rev Med Pharmacol Sci* 2015; 19: 3403-3411.
- 6) SHI J, ZHONG X, SONG Y, WU Z, GAO P, ZHAO J, SUN J, WANG J, LIU J, WANG Z. Long non-coding RNA LINC1-IT1 plays a tumour-suppressive role in colorectal cancer by inhibiting cell proliferation and migration. *Cell Biochem Funct* 2019; 37: 11-20.
- 7) HUA F, LIU S, ZHU L, MA N, JIANG S, YANG J. High-expressed long non-coding RNA NNT-AS1 promotes cell proliferation and invasion through Wnt/ β -catenin signaling pathway in cervical cancer. *Biomed Pharmacother* 2017; 92: 1128-1134.
- 8) LI X, LIN Y, YANG X, WU X, HE X. Long noncoding RNA H19 regulates EZH2 expression by interacting with miR-630 and promotes cell invasion in nasopharyngeal carcinoma. *Biochem Biophys Res Commun* 2016; 473: 913-919.
- 9) CHEN L, SUN L, DONG L, CUI P, XIA Z, LI C, ZHU Y. The role of long noncoding RNA-LET in cell proliferation and invasion of nasopharyngeal carcinoma and its mechanism. *Onco Targets Ther* 2017; 10: 2769-2778.
- 10) CHEN G, SUN W, HUA X, ZENG W, YANG L. Long non-coding RNA FOXD2-AS1 aggravates nasopharyngeal carcinoma carcinogenesis by modulating miR-363-5p/S100A1 pathway. *Gene* 2018; 645: 76-84.
- 11) CHENG Q, XU X, JIANG H, XU L, LI Q. Knockdown of long non-coding RNA XIST suppresses nasopharyngeal carcinoma progression by activating miR-491-5p. *J Cell Biochem* 2018; 119: 3936-3944.
- 12) LESSARD L, LIU M, MARZESE DM, WANG H, CHONG K, KAWAS N, DONOVAN NC, KIYOHARA E, HSU S, NELSON N, IZRAELY S, SAGI-ASSIF O, WITZ IP, MA XJ, LUO Y, HOON D. The CASC15 long intergenic noncoding RNA locus is involved in melanoma progression and phenotype switching. *J Invest Dermatol* 2015; 135: 2464-2474.

- 13) HE T, ZHANG L, KONG Y, HUANG Y, ZHANG Y, ZHOU D, ZHOU X, YAN Y, ZHANG L, LU S, ZHOU J, WANG W. Long non-coding RNA CASC15 is upregulated in hepatocellular carcinoma and facilitates hepatocarcinogenesis. *Int J Oncol* 2017; 51: 1722-1730.
- 14) YAO XM, TANG JH, ZHU H, JING Y. High expression of LncRNA CASC15 is a risk factor for gastric cancer prognosis and promote the proliferation of gastric cancer. *Eur Rev Med Pharmacol Sci* 2017; 21: 5661-5667.
- 15) FERNANDO TR, CONTRERAS JR, ZAMPINI M, RODRIGUEZ-MALAVE NI, ALBERTI MO, ANGUIANO J, TRAN TM, PALANICHAMY JK, GAJETON J, UNG NM, AROS CJ, WATERS EV, CASERO D, BASSO G, PIGAZZI M, RAO DS. The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia. *Mol Cancer* 2017; 16: 126.
- 16) LIU D, LI Y, LUO G, XIAO X, TAO D, WU X, WANG M, HUANG C, WANG L, ZENG F, JIANG G. LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. *Cancer Lett* 2017; 388: 281-291.
- 17) CUI Y, ZHANG F, ZHU C, GENG L, TIAN T, LIU H. Up-regulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/beta-catenin signaling pathway. *Cancer Target* 2017; 8: 17785-17794.
- 18) YAN K, TIAN J, SHI W, XU J, ZHU Y. LncRNA SNHG6 is associated with poor prognosis of gastric cancer and promote cell proliferation and EMT through epigenetically silencing miR-101-3p sponging miR-101-3p. *Cell Physiol Biochem* 2017; 42: 999-1012.
- 19) JIN J, CHU Z, MA J, LI Y, YANG J. Long non-coding RNA SPRY4-IT1 promote proliferation and invasion by acting as a sponge of miR-101-3p in colorectal cancer cells. *Tumour Biol* 2017; 39: 1361-1373.